Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment

Barchart · 2d ago

Planned Review of Standard Deviation Demonstrates No Need to Increase Size of Ongoing LEVEL Study

LEVEL On Track to Complete Enrollment in First Half of 2026; Topline Data Expected in Second Half of 2026

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.